{"analyses":[{"groupDescription":"Week 1 -24","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.2382","statisticalMethod":"Cochran-Mantel-Haenszel"},{"groupDescription":"Week 1 - 48","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.5127","statisticalMethod":"Cochran-Mantel-Haenszel"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.66","upperLimit":"40.46","value":"13.3"},{"groupId":"OG001","lowerLimit":"0.00","upperLimit":"30.85","value":"0"}]}],"title":"Week 1 Through Week 24"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"4.33","upperLimit":"48.09","value":"20.0"},{"groupId":"OG001","lowerLimit":"0.25","upperLimit":"44.50","value":"10.0"}]}],"title":"Week 1 Through Week 48"}],"denoms":[{"counts":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"10"}],"units":"Participants"}],"description":"Percentage of participants who achieved a hematologic improvement in neutrophil response (HI-N) per IWG criteria sustained over any consecutive 56-day (8-week) period, during the treatment period (Week 1 to Week 24 and Week 1 to Week 48) HI-N was defined as at least a 100% increase and an absolute increase \\> 0.5 X 10\\^9/L.","dispersionType":"95% Confidence Interval","groups":[{"description":"Luspatercept 1.0 mg/Kg SC on Day 1 of each 21-day treatment cycle","id":"OG000","title":"Luspatercept"},{"description":"Placebo (Volume equivalent to experimental arm) SC on Day 1 of each 21-day treatment cycle","id":"OG001","title":"Placebo"}],"paramType":"NUMBER","populationDescription":"All treated participants with available measurements","reportingStatus":"POSTED","timeFrame":"Week 1 through Week 24 or Week 1 Through Week 48 of study treatment","title":"Percentage of Participants Who Achieved a Hematologic Improvement in Neutrophil Response (HI-N) Over Any Consecutive 56-day Period","type":"SECONDARY","unitOfMeasure":"Percentage of Participants"}